MicroStockProfit.com announces an investment report featuring Vical Inc. (Nasdaq:VICL). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/ads/VICL
Vical Inc. (VICL) researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has five active independent clinical and preclinical development programs in the areas of infectious disease and cancer, including a fully enrolled Phase III clinical trial using the Company’s Allovectin-7 immunotherapeutic in patients with metastatic melanoma; a fully enrolled Phase II clinical trial using TransVax, its cytomegalovirus (CMV), therapeutic DNA vaccine; completed Phase I clinical trials using its Hemagglutinin Type 5 and Neuraminidase Type 1 pandemic influenza DNA vaccine formulated with its Vaxfectin adjuvant; a preclinical program using its H1N1 pandemic influenza DNA vaccine formulated with its Vaxfectin adjuvant, and a preclinical program using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.
Message Board Search for VICL: http://www.boardcentral.com/boards/VICL
In the report, the analyst notes:
“VICL reported financial results for the year ended December 31, 2009, reporting cash and investments of approximately $53 million at year-end 2009. The Company raised approximately $33 million of net proceeds from the sale of equity securities during 2009, and approximately $3 million of additional net proceeds from the sale of equity securities to date in 2010.
“VICL recently announced that a prime-boost malaria vaccine regimen provided sterile protection, with no disease symptoms and no detectable malaria parasites, in four of 15 vaccinated volunteers a full 28 days after challenge with multiple infected-mosquito bites. The remaining 11 vaccinated volunteers and all six unvaccinated control volunteers developed parasitic infections. Results were presented at the National Foundation for Infectious Diseases (NFID) Thirteenth Annual Conference on Vaccine Research (Bethesda – April 26-28).”